6163银河(国际)线路检测中心-网站入口

首页 /科研细胞 /科研细胞 /科研细胞 /OCI-AML2(人急性髓系白血病)

OCI-AML2(人急性髓系白血病)

CBP60527

询 价
索取STR
产品描述
产品数据库
I. General information 
Synonyms: OCI-AML2
Background: established from the peripheral blood of a 65-year-old man with acute myeloid leukemia (AML FAB M4) in 1986 at diagnosis; cells were described in the literature to express the retinoic acid receptor gene; cell line carries the DNMT3A R635W mutation
Species: human (Homo sapiens)
Tissue: N/A 
Disease: acute myeloid leukemia
Gender: N/A 
Morphology: single, round to oval cells in suspension;
Growth Mode: N/A 
Doubling Time: about 30-50 hours
DNA Profile: N/A
Cobioer’s Cell Line Authentication Service
Culture Medium:

80% MEM α  (GIBCO 12561-056 ) + 20% FBS

OCI-AML2完全培养基,# CBP60527M
We strongly suggest to purchase the complete medium from Cobioer.

Cryopreservation medium: 90%FBS+10%DMSO
Mycoplasma: negative in DAPI, microbiological culture, RNA hybridization assays
Immunology: CD3 -, CD4 +, CD13 +, CD14 -, CD15 +, CD19 -, CD33 +, CD34 -, CD68 +, HLA-DR (+); image
Fingerprint: multiplex PCR of minisatellite markers revealed a unique DNA profile
Species: confirmed as human with IEF of MDH, NP
Cytogenetics: human hyperdiploid karyotype with 3.8% polyploidy - 48(43-49)<2n>XY, +6, +8, der(1)inv(1)(p36q31)t(1;6) (q13;p12), der(2)t(2;17)(p23;q24.1)del(2)(q14.2q36), der(3)t(1;3)(p36;p25), ins(3;2)(q21;q14.2q36), t(5;8)(q11.2;q24), der(6)t(1;6)(q31;p12)t(3;6) (q26;q24), inv(12)(p13.3q13.2), t(13;14)(q32/33;q24.2), der(17)t(2;17)(p23;q24.1) - sideline with +der(5) - carries apparent variant translocations involving several ANLL breakpoints: 1p36, 3q21, 3q26 (megakaryocytic abnormalities), 12p13, 17q24 (FAB-M4)
Virus   ELISA: reverse transcriptase negative; PCR: EBV -, HBV -, HCV -, HIV-1 -, HIV-2 -, HTLV-I/II -, MLV -, SMRV -
Comments: For more information, please contact Cobioer (4008-750-250).
药靶模型联系方式: 华东销售经理:18240630236 全国销售经理:18066071954
诊断标准品联系方式: 华东销售经理:15000320447 华北销售经理:18131625521 华南销售经理:13484295986 华中&西南销售经理:13871580511 全国销售经理:13484295986

扫二维码

立即提交